cardio-symposium

What pre-clinical and clinical results have taught us about the PACCOCATH drug-eluting balloon coating technology 25-May-10 , Paris, France

Wake up to sleep apnoea 18-Oct-09 , Montreal, Canada

CVD - the Need for Early Intervention 18-Oct-09 , Montreal, Canada

What more can we achieve beyond mono and combination therapy for hypertension management? 29-Aug-09 , Barcelona, Spain

Highly purified omega-3 fatty acid ethyl-esters: proven effects and future prospects 01-Sep-09 , Barcelona, Spain

Diabetes and the heart: state-of-the-art treatment strategies 01-Sep-09 , Barcelona, Spain

Management of high-risk patients with type 2 diabetes – a collaborative approach 01-Sep-09 , Barcelona, Spain

Linking sleep apnoea, cardiology and diabetes: what you don't know may surprise you! 31-Aug-09 , Barcelona, Spain

Stand Alone Meeting 2008: A New Dawn in Cardiovascular Protection 26-Sep-08 , Barcelona, Spain

Benefits of cardiac biomarkers in public health 02-Sep-08 , Munich, Germany

New perspectives for an evidence-based therapy with omega-3 fatty acid ethyl esters 02-Sep-08 , Munich, Germany

Cardiovascular Risk Management – From Prevention to Treatment 30-Aug-08 , Munich, Germany

Diabetes and the Heart: Guidelines for the Clinical Practice – Epidemiology, Classification and Pathophysiology 29-Aug-08 , Munich, Germany

Diabetes and the Heart: Guidelines for the Clinical Practice – Treatment of Cardiovascular Disease in the Clinical Practice 29-Aug-08 , Munich, Germany

Beyond blood pressure control: new clinical data with Eprosartan 04-Sep-07 , Vienna, Austria

Consensus recommendation for clinical use of N-Terminal pro B-Type natriuretic peptide (NT-proBNP) 04-Sep-07 , Vienna, Austria

State of the Art Treatment of Atrial Fibrillation: The Arctic Front™ Cryoballoon Catheter 25-Jun-07 , Lisbon, Portugal

Treatment strategies in diabetes and cardiovascular diseases 28-Oct-06 , Berlin, Germany

NT-proBNP – A Key Marker in the Continuum of Cardiac Disease 05-Sep-06 , Barcelona, Spain

Cerebro- and Cardiovascular Risk Reduction with Eprosartan 04-Sep-06 , Barcelona, Spain

B-Type Natriuretic Peptide testing – the latest and greatest in cardiovascular disease assessment 02-Sep-06 , Barcelona, Spain

Clinical Advantages for using NT-proBNP in Heart Failure Patients 19-Jun-06 , Helsinki, Finland

Value of N-terminal pro B-type natriuretic peptide (NT-proBNP) in a wide spectrum of cardiovascular disorders 06-Sep-05 , Stockholm, Sweden

Blood glucose control and beyond: Secondary prevention of stroke with Eprosartan 06-Sep-05 , Stockholm, Sweden

Interpretation of NT-proBNP in specific patient populations 10-May-05 , Glasgow, United Kingdom

The clinical value of biochemical markers in patients with acute dyspnoea and acute chest pain 18-Oct-04 , Rome, Italy

Renal dysfunction in cardiovascular disease. Joint Symposium of the EASD and the German Society of Cardiology 03-Sep-04 , Munich, Germany

Acute coronary syndromes. Joint Symposium of the EASD and the German Society of Cardiology 03-Sep-04 , Munich, Germany

Diagnosis and treatment of chronic heart failure. Joint Symposium of the EASD and the German Society of Cardiology 03-Sep-04 , Munich, Germany

N-terminal pro B-type natriuretic peptide: a new standard for cardiac care 31-Aug-04 , Munich, Germany

Diabetes and the heart 28-Aug-04 , Munich, Germany

Brain Natriuretic Peptide (BNP) as a marker in cardiovascular diseases 28-Aug-04 , Munich, Germany

Ischemia of the heart 28-Aug-04 , Munich, Germany